Comparing of Myovant Sciences Ltd. (MYOV) and Melinta Therapeutics Inc. (NASDAQ:MLNT)

We are contrasting Myovant Sciences Ltd. (NYSE:MYOV) and Melinta Therapeutics Inc. (NASDAQ:MLNT) on their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Myovant Sciences Ltd. N/A 0.00 246.79M -3.80 0.00
Melinta Therapeutics Inc. 65.17M 0.97 133.95M -21.57 0.00

Table 1 shows the top-line revenue, earnings per share and valuation for Myovant Sciences Ltd. and Melinta Therapeutics Inc.

Profitability

Table 2 hightlights the return on assets, return on equity and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Myovant Sciences Ltd. 0.00% -451.3% -153.5%
Melinta Therapeutics Inc. -205.54% -69.8% -33.4%

Liquidity

Myovant Sciences Ltd. has a Current Ratio of 3.5 and a Quick Ratio of 3.5. Competitively, Melinta Therapeutics Inc.’s Current Ratio is 1.3 and has 1 Quick Ratio. Myovant Sciences Ltd.’s better ability to pay short and long-term obligations than Melinta Therapeutics Inc.

Institutional and Insider Ownership

Roughly 30.3% of Myovant Sciences Ltd. shares are held by institutional investors while 61.9% of Melinta Therapeutics Inc. are owned by institutional investors. Myovant Sciences Ltd.’s share held by insiders are 0.1%. Competitively, 8.4% are Melinta Therapeutics Inc.’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Myovant Sciences Ltd. 6.05% 24.62% 20.95% 1.37% 57.94% 40.04%
Melinta Therapeutics Inc. -13.45% 22.01% -55.22% -77.61% -92.23% 29.94%

For the past year Myovant Sciences Ltd. has stronger performance than Melinta Therapeutics Inc.

Summary

Melinta Therapeutics Inc. beats on 5 of the 9 factors Myovant Sciences Ltd.

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for womenÂ’s health and endocrine diseases. The companyÂ’s lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation used in assisted reproduction. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was founded in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

Melinta Therapeutics, Inc., an antibiotics company, is engaged in the discovery, development, and commercialization of antibiotics to overcome drug-resistant, life-threatening infections. It develops Delafloxacin, a fluoroquinolone for acute bacterial skin and skin structure infections caused by Gram-positive and Gram-negative bacteria; and Baxdela for the treatment of patients with acute bacterial skin and skin structure infections. Melinta Therapeutics, Inc. was formerly known as formerly Rib-X Pharmaceuticals and changed its name to Melinta Therapeutics, Inc. on October 7, 2013. The company was founded in 2000 and is headquartered in New Haven, Connecticut with an additional office in Lincolnshire, Illinois.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.